U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory HER2-Negative Breast Carcinoma

MedGen UID:
1715671
•Concept ID:
C5239117
•
Neoplastic Process
Synonyms: Refractory HER2 Negative Breast Adenocarcinoma; Refractory HER2 Negative Breast Carcinoma

Definition

A HER2-negative breast adenocarcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory HER2-Negative Breast Carcinoma

Recent clinical studies

Etiology

Racial and Ethnic Disparity in Preoperative Chemosensitivity and Survival in Patients With Early-Stage Breast Cancer.
Roy AM, Patel A, Catalfamo K, Attwood K, Khoury T, Yao S, Gandhi S
JAMA Netw Open 2023 Nov 1;6(11):e2344517. doi: 10.1001/jamanetworkopen.2023.44517. PMID: 37991763Free PMC Article
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results.
Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, Decker T, Boyle F, McCune S, Armstrong A, Shannon C, Bertelli G, Chang CW, Desai R, Gupta K, Wilson TR, Flechais A, Bardia A
Clin Cancer Res 2022 Aug 2;28(15):3256-3267. doi: 10.1158/1078-0432.CCR-21-3811. PMID: 35583555Free PMC Article
Predictive and prognostic significance of BRCAness in HER2-negative breast cancer.
Sueta A, Yamamoto-Ibusuki M, Tomiguchi M, Fujiki Y, Goto-Yamaguchi L, Iwase H, Yamamoto Y
Breast Cancer 2022 Mar;29(2):368-376. Epub 2022 Jan 5 doi: 10.1007/s12282-021-01319-9. PMID: 34985726
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR(+)/HER2(-) Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).
Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Rugo HS, Purkayastha D, Moulder S
Clin Cancer Res 2021 Aug 1;27(15):4177-4185. Epub 2021 Mar 15 doi: 10.1158/1078-0432.CCR-20-2114. PMID: 33722897Free PMC Article
Everolimus.
Hasskarl J
Recent Results Cancer Res 2018;211:101-123. doi: 10.1007/978-3-319-91442-8_8. PMID: 30069763

Diagnosis

Beyond failure of endocrine-based therapies in HR+/HER2 negative advanced breast cancer: What before chemotherapy? A glimpse into the future.
Torrisi R, Gerosa R, Miggiano C, Saltalamacchia G, Benvenuti C, Santoro A
Crit Rev Oncol Hematol 2025 Apr;208:104634. Epub 2025 Feb 1 doi: 10.1016/j.critrevonc.2025.104634. PMID: 39900320
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study.
Ni M, Zhou L, Lu Y, Guo D, Li X, Li L, Zhang L, Chen M, Zhang L, Xu F, Yuan Z, Wang S, Shi Y, Yang A, An X
BMC Cancer 2024 Sep 30;24(1):1214. doi: 10.1186/s12885-024-12953-9. PMID: 39350055Free PMC Article
Racial and Ethnic Disparity in Preoperative Chemosensitivity and Survival in Patients With Early-Stage Breast Cancer.
Roy AM, Patel A, Catalfamo K, Attwood K, Khoury T, Yao S, Gandhi S
JAMA Netw Open 2023 Nov 1;6(11):e2344517. doi: 10.1001/jamanetworkopen.2023.44517. PMID: 37991763Free PMC Article
Predictive and prognostic significance of BRCAness in HER2-negative breast cancer.
Sueta A, Yamamoto-Ibusuki M, Tomiguchi M, Fujiki Y, Goto-Yamaguchi L, Iwase H, Yamamoto Y
Breast Cancer 2022 Mar;29(2):368-376. Epub 2022 Jan 5 doi: 10.1007/s12282-021-01319-9. PMID: 34985726
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN, Cristofanilli M
Curr Treat Options Oncol 2017 Jan;18(1):6. doi: 10.1007/s11864-017-0443-7. PMID: 28197838

Therapy

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.
Hamilton E, Oliveira M, Turner N, García-Corbacho J, Hernando C, Ciruelos EM, Kabos P, Ruiz-Borrego M, Armstrong A, Patel MR, Vaklavas C, Twelves C, Boni V, Incorvati J, Brier T, Gibbons L, Klinowska T, Lindemann JPO, Morrow CJ, Sykes A, Baird RD
Ann Oncol 2024 Aug;35(8):707-717. Epub 2024 May 8 doi: 10.1016/j.annonc.2024.04.012. PMID: 38729567
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results.
Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, Decker T, Boyle F, McCune S, Armstrong A, Shannon C, Bertelli G, Chang CW, Desai R, Gupta K, Wilson TR, Flechais A, Bardia A
Clin Cancer Res 2022 Aug 2;28(15):3256-3267. doi: 10.1158/1078-0432.CCR-21-3811. PMID: 35583555Free PMC Article
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR(+)/HER2(-) Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).
Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Rugo HS, Purkayastha D, Moulder S
Clin Cancer Res 2021 Aug 1;27(15):4177-4185. Epub 2021 Mar 15 doi: 10.1158/1078-0432.CCR-20-2114. PMID: 33722897Free PMC Article
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, Shah PD, Ballinger TJ, Yang ES, Vinayak S, Melisko M, Brufsky A, DeMeo M, Jenkins C, Domchek S, D'Andrea A, Lin NU, Hughes ME, Carey LA, Wagle N, Wulf GM, Krop IE, Wolff AC, Winer EP, Garber JE
J Clin Oncol 2020 Dec 20;38(36):4274-4282. Epub 2020 Oct 29 doi: 10.1200/JCO.20.02151. PMID: 33119476
Copanlisib: First Global Approval.
Markham A
Drugs 2017 Dec;77(18):2057-2062. doi: 10.1007/s40265-017-0838-6. PMID: 29127587

Prognosis

Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast Cancer.
El Kaddissi A, Vernerey D, Falcoz A, Mansi L, Bazan F, Chaigneau L, Dobi E, Goujon M, Meneveau N, Paillard MJ, Selmani Z, Viot J, Molimard C, Monnien F, Woronoff AS, Curtit E, Borg C, Meynard G
Clin Breast Cancer 2024 Oct;24(7):e622-e632.e5. Epub 2024 Jun 19 doi: 10.1016/j.clbc.2024.06.006. PMID: 38972830
Racial and Ethnic Disparity in Preoperative Chemosensitivity and Survival in Patients With Early-Stage Breast Cancer.
Roy AM, Patel A, Catalfamo K, Attwood K, Khoury T, Yao S, Gandhi S
JAMA Netw Open 2023 Nov 1;6(11):e2344517. doi: 10.1001/jamanetworkopen.2023.44517. PMID: 37991763Free PMC Article
Predictive and prognostic significance of BRCAness in HER2-negative breast cancer.
Sueta A, Yamamoto-Ibusuki M, Tomiguchi M, Fujiki Y, Goto-Yamaguchi L, Iwase H, Yamamoto Y
Breast Cancer 2022 Mar;29(2):368-376. Epub 2022 Jan 5 doi: 10.1007/s12282-021-01319-9. PMID: 34985726
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer.
Shah AN, Flaum L, Helenowski I, Santa-Maria CA, Jain S, Rademaker A, Nelson V, Tsarwhas D, Cristofanilli M, Gradishar W
J Immunother Cancer 2020 Feb;8(1) doi: 10.1136/jitc-2019-000173. PMID: 32060053Free PMC Article
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN, Cristofanilli M
Curr Treat Options Oncol 2017 Jan;18(1):6. doi: 10.1007/s11864-017-0443-7. PMID: 28197838

Clinical prediction guides

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.
Hamilton E, Oliveira M, Turner N, García-Corbacho J, Hernando C, Ciruelos EM, Kabos P, Ruiz-Borrego M, Armstrong A, Patel MR, Vaklavas C, Twelves C, Boni V, Incorvati J, Brier T, Gibbons L, Klinowska T, Lindemann JPO, Morrow CJ, Sykes A, Baird RD
Ann Oncol 2024 Aug;35(8):707-717. Epub 2024 May 8 doi: 10.1016/j.annonc.2024.04.012. PMID: 38729567
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results.
Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, Decker T, Boyle F, McCune S, Armstrong A, Shannon C, Bertelli G, Chang CW, Desai R, Gupta K, Wilson TR, Flechais A, Bardia A
Clin Cancer Res 2022 Aug 2;28(15):3256-3267. doi: 10.1158/1078-0432.CCR-21-3811. PMID: 35583555Free PMC Article
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR(+)/HER2(-) Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).
Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Rugo HS, Purkayastha D, Moulder S
Clin Cancer Res 2021 Aug 1;27(15):4177-4185. Epub 2021 Mar 15 doi: 10.1158/1078-0432.CCR-20-2114. PMID: 33722897Free PMC Article
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, Shah PD, Ballinger TJ, Yang ES, Vinayak S, Melisko M, Brufsky A, DeMeo M, Jenkins C, Domchek S, D'Andrea A, Lin NU, Hughes ME, Carey LA, Wagle N, Wulf GM, Krop IE, Wolff AC, Winer EP, Garber JE
J Clin Oncol 2020 Dec 20;38(36):4274-4282. Epub 2020 Oct 29 doi: 10.1200/JCO.20.02151. PMID: 33119476
Immunotherapy for metastatic breast cancer.
Sugie T
Chin Clin Oncol 2018 Jun;7(3):28. doi: 10.21037/cco.2018.05.05. PMID: 30056730

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...